NCT06322342 2025-12-26Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast AgentReveal Pharmaceuticals Inc.Phase 2 Completed18 enrolled
NCT03962543 2025-08-07ReNeuSpringWorks Therapeutics, Inc.Phase 2 Active not recruiting114 enrolled 25 charts 1 FDA